Hidaka
Japan
Saitama Medical University International Medical Center (SIMC)
ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor
ovarian cancer, intraperitoneal chemotherapy, immune response
Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi